• Exponent Reports Third Quarter of Fiscal Year 2021 Financial Results

    Source: Nasdaq GlobeNewswire / 28 Oct 2021 16:04:00   America/New_York

    MENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the third quarter of fiscal year 2021 ended October 1, 2021.

    “Our differentiated capabilities, which marry high-quality data analytics with deep subject matter expertise, drove continued outperformance in the third quarter of 2021. For the quarter, net revenue grew 16%, while EBITDA1 margin expanded more than 350 basis points from the prior year period,” commented Dr. Catherine Corrigan, President and Chief Executive Officer. “Given the increasing demand for our unique offering, growing our world-class team remains a top priority. The velocity and caliber of new starts over the last few months continues to demonstrate our ability to attract the best and brightest, despite the competitive market for engineering and scientific talent. As a result, we are in an excellent position to drive profitable growth and scale across various end markets.”

    “During the third quarter, our reactive business further benefitted from the post-COVID acceleration of litigation throughput in our court systems, and at the same time, our proactive engagements, such as user and machine learning data studies, remained a key driver of growth. Our work continued to be robust and diverse, with climate vulnerability assessments with utilities, risk assessments in chemicals, ongoing energy storage-related work, and projects in the automotive and consumer products industries further demonstrating the strength of our long-term strategy,” continued Dr. Corrigan.

    Third Quarter Financial Results

    Total revenues and revenues before reimbursements for the third quarter of 2021 increased 18% to $116.4 million and 16% to $108.5 million as compared to $98.7 million and $93.5 million in the third quarter of 2020, respectively.

    Net income increased to $24.6 million, or $0.46 per diluted share, in the third quarter of 2021, as compared to $18.1 million, or $0.34 per diluted share, in the same period of 2020. The tax benefit for the classification of tax adjustments associated with share-based awards realized in the third quarter of 2021 was $1.1 million, as compared to $0 in the third quarter of 2020. Inclusive of the tax benefit, Exponent’s consolidated tax rate was 24.1% in the third quarter, as compared to 26.6% for the same period in 2020.

    EBITDA1 increased to $34.0 million, or 31.4% of net revenues, in the third quarter of 2021, as compared to $26.0 million, or 27.8% of net revenues in the third quarter of 2020.

    Year to Date Financial Results

    Total revenues and revenues before reimbursements for the first three quarters of 2021 increased 19% to $352.8 million and 18% to $330.5 million, respectively, as compared to $296.7 million and $281.1 million in the same period one year ago.

    Net income increased to $80.8 million, or $1.52 per diluted share, through the first three quarters of 2021, as compared to $60.7 million, or $1.14 per diluted share, in the same period of 2020. The tax benefit for the classification of tax adjustments associated with share-based awards realized through the first three quarters of 2021 was $9.9 million, as compared to $9.7 million during the same period one year ago. Inclusive of the tax benefit, Exponent’s consolidated tax rate was 16.8% through the first three quarters of 2021, as compared to 13.4% in the same period last year.

    EBITDA1 increased to $102.1 million, or 30.9% of net revenues, through the first three quarters of 2021, as compared to $73.8 million, or 26.3% of net revenues, in the same period of 2020.

    During the first three quarters of 2021, Exponent paid $32.8 million in dividends, repurchased $7 million of common stock, and closed the period with $254.8 million in cash, cash equivalents and short-term investments.

    Business Overview

    Exponent’s engineering and other scientific segment represented 83% of the Company’s net revenues in the third quarter 2021. Net revenues in this segment increased 20% in the third quarter as compared to the prior year period. Growth during the quarter was broad-based, with continued strong demand for Exponent's services across a number of industries and use cases, which includes a steady increase in litigation support, human participant studies for the consumer products segment, work with wearable technologies, as well as asset integrity and risk management engagements for utilities. On the automotive side, Exponent has further progressed its work supporting advanced driver assistance systems and the implementation of safety frameworks for advanced vehicles and energy storage.

    Exponent’s environmental and health segment represented 17% of the Company’s net revenues in the third quarter. Net revenues in this segment were approximately flat in the third quarter of 2021 as compared to the prior year period. Exponent’s focused efforts in the pharmaceutical industry continue to materialize through its emphasis on recruitment and development, which has supported new client engagements. The pharmaceutical industry remains a significant opportunity for the Company as it leverages its multidisciplinary approach across the full product life cycle.

    Business Outlook

    “As we finish out 2021, demand for our multidisciplinary services continues to grow as our offerings and markets expand. However, as we add headcount, we do anticipate a moderation in utilization as we have discussed over the last two quarters,” commented Richard Schlenker, Executive Vice President and Chief Financial Officer.

    For the fourth quarter of 2021 as compared to the same period one year prior, Exponent anticipates:

    • Revenues before reimbursements to grow in the mid-single digits; and,
    • EBITDA1 margin to decrease 175 to 225 basis points.

    For the full year 2021 as compared to the same period one year prior, Exponent anticipates:

    • Revenues before reimbursements to grow in the mid-teens; and,
    • EBITDA1 margin to increase 290 to 310 basis points.

    “Through our highly specialized offering, we are partnering with clients to address their most complex challenges, and the increased level of new engagements across our broad-based portfolio has continued to support consistent, profitable growth. Exponent remains well-positioned to help unravel the complexities of innovations as they become reality, and as society continues to raise expectations for safety, health, sustainability, and reliability, which ultimately will drive long-term value for our shareholders,” concluded Dr. Corrigan.

    Today's Conference Call Information

    Exponent will discuss its financial results in more detail on a conference call today, Thursday, October 28, 2021, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The audio of the conference call is available by dialing (800) 367-2403 or (334) 777-6978. A live webcast of the call will be available on the Investor Relations section of the Company's website at www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent website, or by dialing (888) 203-1112 or (719) 457-0820 and entering passcode 7178253#.

    Footnotes

    1 EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the measures to GAAP is set forth below.

    About Exponent

    Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent's interdisciplinary organization of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 50 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges of sustainability.

    Exponent may be reached at (888) 656­-EXPO, info@exponent.com, or www.exponent.com.

    Forward Looking Statements

    This news release contains, and incorporates by reference, certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. When used in this document and in the documents incorporated herein by reference, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the COVID-19 pandemic (including factors relating to measures implemented by governmental authorities or by us to promote the safety of our employees, vendors and clients; other direct and indirect impacts on our business and the businesses of our clients, vendors and other partners; impacts which may, among other things, adversely affect our clients’ ability to utilize our services at the levels they have previously; disruptions of access to our facilities or those of our clients or third parties; and increased and potentially significant economic uncertainty and volatility, including credit and collectability risks and potential disruptions of capital and credit markets), the possibility that the demand for our services may decline as a result of changes in generally applicable and industry-specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10-K under the heading “Risk Factors” and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

    Source: Exponent, Inc.

     
    EXPONENT, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF INCOME
    For the Quarters Ended October 1, 2021 and October 2, 2020
    (unaudited)
    (in thousands, except per share data)
              
          
       Quarter Ended Nine Months Ended
       October 1, October 2, October 1, October 2,
       2021
     2020
     2021
     2020
              
    Revenues       
     Revenues before reimbursements$108,467  $93,499  $330,514  $281,082 
     Reimbursements 7,938   5,164   22,249   15,579 
              
      Revenues 116,405   98,663   352,763   296,661 
              
    Operating expenses       
     Compensation and related expenses 64,138   62,419   210,491   180,541 
     Other operating expenses 8,017   7,839   23,848   23,736 
     Reimbursable expenses 7,938   5,164   22,249   15,579 
     General and administrative expenses 4,193   2,834   10,626   11,290 
              
        84,286   78,256   267,214   231,146 
              
      Operating income 32,119   20,407   85,549   65,515 
              
    Other income (expense), net        
     Interest income, net 13   316   54   1,496 
     Miscellaneous income, net 257   3,915   11,579   3,096 
        270   4,231   11,633   4,592 
              
      Income before income taxes 32,389   24,638   97,182   70,107 
              
    Income taxes 7,815   6,554   16,360   9,395 
              
              
      Net income$24,574  $18,084  $80,822  $60,712 
              
              
    Net income per share:       
     Basic$0.47  $0.35  $1.54  $1.16 
     Diluted$0.46  $0.34  $1.52  $1.14 
              
    Shares used in per share computations:       
     Basic 52,618   52,316   52,597   52,383 
     Diluted 53,312   53,209   53,316   53,342 
              


     
    EXPONENT, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
    October 2, 2020 and January 3, 2020
    (unaudited)
    (in thousands)
           
           
        October 1, January 1,
        2021 2021
       Assets   
    Current assets:   
     Cash and cash equivalents$229,785  $197,525 
     Short-term investments 24,998   45,001 
     Accounts receivable, net 144,039   111,565 
     Prepaid expenses and other assets 18,738   12,741 
      Total current assets 417,560   366,832 
    Property, equipment and leasehold improvements, net 60,082   59,823 
    Operating lease right-of-use asset 15,777   19,322 
    Goodwill 8,607   8,607 
    Other assets 136,279   125,512 
        $638,305  $580,096 
           
       Liabilities and Stockholders' Equity   
    Current liabilities:   
     Accounts payable and accrued liabilities$21,443  $16,327 
     Accrued payroll and employee benefits 87,179   83,194 
     Deferred revenues 12,192   11,800 
     Operating lease liability 5,604   5,987 
      Total current liabilities 126,418   117,308 
    Other liabilities 96,189   86,947 
    Operating lease liability 10,709   14,343 
      Total liabilities 233,316   218,598 
           
    Stockholders' equity:   
     Common stock 66   66 
     Additional paid-in capital 279,250   265,328 
     Accumulated other comprehensive loss (2,052)  (1,932)
     Retained earnings 468,578   421,809 
     Treasury stock, at cost (340,853)  (323,773)
       Total stockholders' equity 404,989   361,498 
        $638,305  $580,096 
           


     
    EXPONENT, INC.
    EBITDA and EBITDAS (1)
    For the Quarters Ended October 1, 2021 and October 2, 2020
    (unaudited)
    (in thousands)
              
          
       Quarter Ended Nine Months Ended
       October 1, October 2, October 1, October 2,
       2021 2020 2021 2020
              
    Net Income$24,574  $18,084  $80,822  $60,712 
              
    Add back (subtract):       
              
     Income taxes 7,815   6,554   16,360   9,395 
     Interest income, net (13)  (316)  (54)  (1,496)
     Depreciation and amortization 1,645   1,689   4,943   5,176 
              
      EBITDA (1) 34,021   26,011   102,071   73,787 
              
     Stock-based compensation 4,365   3,726   15,239   13,326 
              
      EBITDAS (1)$38,386  $29,737  $117,310  $87,113 
              
              
              
    (1) EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.
              


    Primary Logo

Share on,